AU Patent

AU2020270303B2 — Compound used as kinase inhibitor and application thereof

Assigned to TYK Medicines Inc · Expires 2023-09-07 · 3y expired

What this patent protects

Provided is the compound represented by formula I, or tautomer thereof, or meso thereof, racemate thereof, and mixture of meso and racemate thereof, or enantiomer thereof, diastereomer, and mixture of enantiomer and diastereomer, or pharmaceutically acceptable salt thereof, or de…

USPTO Abstract

Provided is the compound represented by formula I, or tautomer thereof, or meso thereof, racemate thereof, and mixture of meso and racemate thereof, or enantiomer thereof, diastereomer, and mixture of enantiomer and diastereomer, or pharmaceutically acceptable salt thereof, or deuterate thereof. The compound of formula I can be used as a kinase inhibitor, as a drug for the treatment of ROS1, NTRK, ALK, and other kinase-mediated diseases.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020270303B2
Jurisdiction
AU
Classification
—
Expires
2023-09-07
Drug substance claim
No
Drug product claim
No
Assignee
TYK Medicines Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.